Cargando…

The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes

Introduction: The most common side effect of ticagrelor is dyspnea, which leads to premature withdrawal of this life-saving medication in 6.5% of patients. Increased chemoreceptors’ sensitivity was suggested as a possible pathophysiological explanation of this phenomenon; however, the link between o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tubek, Stanislaw, Niewinski, Piotr, Langner-Hetmanczuk, Anna, Jura, Maksym, Kuliczkowski, Wiktor, Reczuch, Krzysztof, Ponikowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394699/
https://www.ncbi.nlm.nih.gov/pubmed/37538377
http://dx.doi.org/10.3389/fphys.2023.1214893
_version_ 1785083429996462080
author Tubek, Stanislaw
Niewinski, Piotr
Langner-Hetmanczuk, Anna
Jura, Maksym
Kuliczkowski, Wiktor
Reczuch, Krzysztof
Ponikowski, Piotr
author_facet Tubek, Stanislaw
Niewinski, Piotr
Langner-Hetmanczuk, Anna
Jura, Maksym
Kuliczkowski, Wiktor
Reczuch, Krzysztof
Ponikowski, Piotr
author_sort Tubek, Stanislaw
collection PubMed
description Introduction: The most common side effect of ticagrelor is dyspnea, which leads to premature withdrawal of this life-saving medication in 6.5% of patients. Increased chemoreceptors’ sensitivity was suggested as a possible pathophysiological explanation of this phenomenon; however, the link between oversensitization of peripheral and/or central chemosensory areas and ticagrelor intake has not been conclusively proved. Methods: We measured peripheral chemoreceptors’ sensitivity using hypoxic ventilatory response (HVR), central chemoreceptors’ sensitivity using hypercapnic hyperoxic ventilatory response (HCVR), and dyspnea severity before and 4 ± 1 weeks following ticagrelor initiation in 11 subjects with chronic coronary syndrome undergoing percutaneous coronary intervention (PCI). The same tests were performed in 11 age-, sex-, and BMI-matched patients treated with clopidogrel. The study is registered at ClinicalTrials.com at NCT05080478. Results: Ticagrelor significantly increased both HVR (0.52 ± 0.46 vs. 0.84 ± 0.69 L min(-1) %(−1); p < 0.01) and HCVR (1.05 ± 0.64 vs. 1.75 ± 1.04 L min(−1) mmHg(−1); p < 0.01). The absolute change in HVR correlated with the change in HCVR. Clopidogrel administration did not significantly influence HVR (0.63 ± 0.32 vs. 0.58 ± 0.33 L min(-1)%(−1); p = 0.53) and HCVR (1.22 ± 0.67 vs. 1.2 ± 0.64 L min(−1) mmHg(−1); p = 0.79). Drug-related dyspnea was reported by three subjects in the ticagrelor group and by none in the clopidogrel group. These patients were characterized by either high baseline HVR and HCVR or excessive increase in HVR following ticagrelor initiation. Discussion: Ticagrelor, contrary to clopidogrel, sensitizes both peripheral and central facets of chemodetection. Two potential mechanisms of ticagrelor-induced dyspnea have been identified: 1) high baseline HVR and HCVR or 2) excessive increase in HVR or HVR and HCVR. Whether other patterns of changes in chemosensitivities play a role in the pathogenesis of this phenomenon needs to be further investigated.
format Online
Article
Text
id pubmed-10394699
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103946992023-08-03 The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes Tubek, Stanislaw Niewinski, Piotr Langner-Hetmanczuk, Anna Jura, Maksym Kuliczkowski, Wiktor Reczuch, Krzysztof Ponikowski, Piotr Front Physiol Physiology Introduction: The most common side effect of ticagrelor is dyspnea, which leads to premature withdrawal of this life-saving medication in 6.5% of patients. Increased chemoreceptors’ sensitivity was suggested as a possible pathophysiological explanation of this phenomenon; however, the link between oversensitization of peripheral and/or central chemosensory areas and ticagrelor intake has not been conclusively proved. Methods: We measured peripheral chemoreceptors’ sensitivity using hypoxic ventilatory response (HVR), central chemoreceptors’ sensitivity using hypercapnic hyperoxic ventilatory response (HCVR), and dyspnea severity before and 4 ± 1 weeks following ticagrelor initiation in 11 subjects with chronic coronary syndrome undergoing percutaneous coronary intervention (PCI). The same tests were performed in 11 age-, sex-, and BMI-matched patients treated with clopidogrel. The study is registered at ClinicalTrials.com at NCT05080478. Results: Ticagrelor significantly increased both HVR (0.52 ± 0.46 vs. 0.84 ± 0.69 L min(-1) %(−1); p < 0.01) and HCVR (1.05 ± 0.64 vs. 1.75 ± 1.04 L min(−1) mmHg(−1); p < 0.01). The absolute change in HVR correlated with the change in HCVR. Clopidogrel administration did not significantly influence HVR (0.63 ± 0.32 vs. 0.58 ± 0.33 L min(-1)%(−1); p = 0.53) and HCVR (1.22 ± 0.67 vs. 1.2 ± 0.64 L min(−1) mmHg(−1); p = 0.79). Drug-related dyspnea was reported by three subjects in the ticagrelor group and by none in the clopidogrel group. These patients were characterized by either high baseline HVR and HCVR or excessive increase in HVR following ticagrelor initiation. Discussion: Ticagrelor, contrary to clopidogrel, sensitizes both peripheral and central facets of chemodetection. Two potential mechanisms of ticagrelor-induced dyspnea have been identified: 1) high baseline HVR and HCVR or 2) excessive increase in HVR or HVR and HCVR. Whether other patterns of changes in chemosensitivities play a role in the pathogenesis of this phenomenon needs to be further investigated. Frontiers Media S.A. 2023-07-19 /pmc/articles/PMC10394699/ /pubmed/37538377 http://dx.doi.org/10.3389/fphys.2023.1214893 Text en Copyright © 2023 Tubek, Niewinski, Langner-Hetmanczuk, Jura, Kuliczkowski, Reczuch and Ponikowski. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Tubek, Stanislaw
Niewinski, Piotr
Langner-Hetmanczuk, Anna
Jura, Maksym
Kuliczkowski, Wiktor
Reczuch, Krzysztof
Ponikowski, Piotr
The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes
title The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes
title_full The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes
title_fullStr The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes
title_full_unstemmed The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes
title_short The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes
title_sort effects of p2y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394699/
https://www.ncbi.nlm.nih.gov/pubmed/37538377
http://dx.doi.org/10.3389/fphys.2023.1214893
work_keys_str_mv AT tubekstanislaw theeffectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT niewinskipiotr theeffectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT langnerhetmanczukanna theeffectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT juramaksym theeffectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT kuliczkowskiwiktor theeffectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT reczuchkrzysztof theeffectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT ponikowskipiotr theeffectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT tubekstanislaw effectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT niewinskipiotr effectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT langnerhetmanczukanna effectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT juramaksym effectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT kuliczkowskiwiktor effectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT reczuchkrzysztof effectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes
AT ponikowskipiotr effectsofp2y12adenosinereceptorsinhibitorsoncentralandperipheralchemoreflexes